Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news


Alexion VP speaks on access

Posted 18 November 2020

Alexion is hoping to change its market access fortunes for its portfolio of rare disease products in Australia after failing to get several new therapies past the PBAC and to secure listing of a recommended rare disease therapy.

The company is in the process of appointing a government affairs and policy director - a newly created local role which it hopes will help it breakthrough the PBAC to get its newer drugs reimbursed on the PBS.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Top of the Hill
Picking the path out of Covid
Now is not the time for leaders to play it safe
Special Report
Aust Covid Vaccine Tracker
UPDATE: Gilead hits back at WHO over remdesivir
Approvals Action
Trio of new drugs on ARTG
Roche, Seqirus, Clinuvel enlarge local portfolios